Canaccord Genuity analyst William Plovanic maintained a Buy rating on Penumbra (NYSE:PEN) on Wednesday, setting a price target of $335, which is approximately 15.95% above the present share price of $288.93.
Plovanic expects Penumbra to post earnings per share (EPS) of $0.10 for the second quarter of 2021.
The current consensus among 4 TipRanks analysts is for a Strong Buy rating of shares in Penumbra, with an average price target of $323.33.
The analysts price targets range from a high of $335 to a low of $310.
In its latest earnings report, released on 12/31/2020, the company reported a quarterly revenue of $166.9 million and a net profit of -$1.75 million. The company's market cap is $10.54 billion.
According to TipRanks.com, Canaccord Genuity analyst William Plovanic is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 6.0% and a 53.55% success rate.
Penumbra, Inc. engages in the design, development, manufacture, and marketing of innovative medical devices. It offers thrombectomy, embolization, access, neurosurgical tools, ruby coil system, lantern, penumbra occlusion device (POD) system, packing coil, and indigo systems products. Its target markets include interventional neuroradiologists, neurosurgeons, and interventional neurologists; and interventional radiologists, vascular surgeons, and interventional cardiologists. The company was founded by Arani Bose and Adam Elsesser on June 21, 2004 and is headquartered in Alameda, CA.